{
    "clinical_study": {
        "@rank": "117832", 
        "arm_group": [
            {
                "arm_group_label": "Daratumumab 8 milligram per kilogram (mg/kg)", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation."
            }, 
            {
                "arm_group_label": "Daratumumab 16 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the tolerability and safety of Daratumumab in\n      Japanese participants with relapsed (the return of a medical problem) or refractory (not\n      responding to treatment) multiple myeloma (cancer of plasma cells in bone marrow,\n      characterized by the presence of abnormal proteins in the blood)."
        }, 
        "brief_title": "A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1, open-label (all participants and study personnel will know the identity\n      of the study treatments) and multicenter (study conducted at multiple sites) study in\n      Japanese participants. The study will include a Screening Phase, a Treatment Phase, and a\n      Follow-up Phase. The Treatment Phase consists of 2 parts: intense dosing regimen and less\n      intense dosing regimen. Follow-up phase will be until 8 weeks after last dose\n      administration/death/lost to follow up/consent withdrawal for study participation or study\n      end, whichever occurs first. The primary endpoints will be Dose Limiting Toxicity (DLTs) and\n      overall Adverse Events (AEs) profiling. Participants' safety will be monitored throughout\n      the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants proven to have symptomatic (having symptoms) multiple myeloma according\n             the International Myeloma Working Group (IMWG) diagnostic criteria\n\n          -  Participant must have measurable disease defined by either or both the following\n             measurements: a) Serum M-protein greater than or equal to (>=) 1 gram per deciliter\n             (g/dL) (>=10 gram per liter [g/L]) (except for serum immunoglobulin A [IgA] M-protein\n             >= 0.5 g/dL); b) Urine M-protein >=200 milligram per 24 hour (mg/24 h); in case\n             immunoglobulin D [IgD] or immunoglobulin E [IgE] M-protein, quantification should be\n             performed\n\n          -  Participant must have relapsed or refractory multiple myeloma after receiving at\n             least 2 previous therapies, and without further established treatment options\n\n          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status\n             score of 0, 1, or 2\n\n          -  Participant must have life expectancy greater than (>) 3 months\n\n        Exclusion Criteria:\n\n          -  Participant has received daratumumab or other anti-cluster of differentiation 38\n             (anti-CD38) therapies previously\n\n          -  Participant has received anti-myeloma treatment within 2 weeks before administration\n             of the study drug\n\n          -  Participant has previously received an allogenic stem cell transplant; or participant\n             has received autologous stem cell transplantation (ASCT) within 12 weeks before\n             administration of the study drug\n\n          -  Participant has a history of malignancy (other than multiple myeloma) within 5 years\n             before administration of the study drug\n\n          -  Participant is exhibiting clinical signs of meningeal involvement of multiple myeloma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116569", 
            "org_study_id": "CR104072", 
            "secondary_id": "54767414MMY1002"
        }, 
        "intervention": {
            "arm_group_label": [
                "Daratumumab 8 milligram per kilogram (mg/kg)", 
                "Daratumumab 16 mg/kg"
            ], 
            "description": "Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.", 
            "intervention_name": "Daratumumab", 
            "intervention_type": "Drug", 
            "other_name": "JNJ-54767414"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Multiple Myeloma", 
            "Daratumumab", 
            "JNJ-54767414", 
            "Phase 1", 
            "Relapse", 
            "Refractory"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR104072"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Study of JNJ-54761414 (Daratumumab) in Japanese Patients With Relapsed or Refractory Multiple Myeloma", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Pharmaceutical K.K.", 
            "last_name": "Janssen Pharmaceutical K.K., Japan Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The Dose-Limiting Toxicities (DLTs) are based on drug-related adverse events and defined as any of the following events: Infusion-related reactions,  non-hematologic toxicity of Grade 3 or higher, or hematologic toxicity.", 
                "measure": "Number of Participants With Dose Limiting Toxicities (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 up to Day 36"
            }, 
            {
                "description": "An AE is any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.", 
                "measure": "Number of Participants affected by Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 4 Weeks after the last dose of study drug administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Overall Response rate is defined according to Internal Myeloma Working Group criteria based on participants achieving greater than or equal to (>=) partial Response, including participants achieving stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR). Percentage of  participants with overall response will be reported.", 
                "measure": "Percentage of Participants With Overall Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline until disease progression, unmanageable adverse event or death, whichever occurs first, up to 1 year"
            }, 
            {
                "description": "Time to response is defined as the time from the date of first dose of study treatment to the date of the first documentation of observed response.", 
                "measure": "Time to Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline until first documented response or up to 1 year"
            }
        ], 
        "source": "Janssen Pharmaceutical K.K.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Pharmaceutical K.K.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}